Anemia is a global public health concern and is closely linked to dysfunction of brain cognitive neural networks, a key mechanism underlying cognitive impairment. Such deficits-including declines in memory, learning, processing speed, and executive function-reduce daily living abilities and increase risks of falls and depression.
Functional near-infrared spectroscopy (fNIRS) enables real-time monitoring of oxygenated and deoxygenated hemoglobin fluctuations, reflecting brain network function. This study aims to identify affected neural network regions in anemic patients and visualize connectivity changes using heatmaps and arc-based mapping. The findings will support early detection of cognitive impairment and guide precise clinical interventions, ultimately informing individualized treatment strategies to enhance therapeutic outcomes and quality of life.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis of anemia
* First hospitalization
* Male or female, aged 18-65 years
* Willing and able to comply with the requirements for this study and written informed consent
Exclusion Criteria:
* History of psychiatric illness
* History of severe brain disease
* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Primary outcome measure(s)
Concentration changes in oxygenated hemoglobin (HbO) and de-oxygenated hemoglobin (HbR) — Patients will be assessed within 48 hours of admission. Functional Near Infrared Spectroscopy (fNIRS) is a non-invasive brain imaging modality, that can be used to measure HbO and HbR concentrations.
Cognitive Function Assessment — Patients will be assessed within 48 hours of admission. Montreal Cognitive Assessment (MoCA) is used to assess cognitive function in patients, with higher total scores indicating better cognitive function. The total score range is 0 to 30.
Trial sites (1)
Facility
City
Region
Status
Regenerative Medicine Center
Tianjin
Tianjin Municipality
Recruiting
More Institute of Hematology & Blood Diseases Hospital, China trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.